For how we live.
In nearly 40,000 UK women, abnormal blood pressure six weeks after a hypertensive pregnancy roughly doubled later cardiovascular disease. A Dutch cohort shows pregnancy history sharpens risk prediction.
A Global Burden of Disease analysis of Kenya's 47 counties found ischaemic stroke killed 11,328 people in 2023 — death rates are falling even as new cases rise, with raised blood pressure behind 35% of the burden.
Across 27 trials and 88,830 people, each 10-mmHg drop in systolic pressure cut cardiovascular events whether or not the kidneys were impaired — while aggressive lowering nudged up short-term markers of kidney decline.
Added to an SGLT2 inhibitor, the aldosterone-synthase inhibitor cut office systolic pressure 7.5 mm Hg and albuminuria about a quarter in 59 adults with CKD. Kidney function dipped slightly; the maker funded it.
In the phase 3 Bax24 trial, the aldosterone-synthase inhibitor cut 24-hour ambulatory systolic pressure 14.0 mm Hg more than placebo over 12 weeks. AstraZeneca funded it, and three patients developed high potassium.
Garlic supplements modestly lower blood pressure in hypertensive people, and may nudge cholesterol down a little. The cold-prevention evidence rests on a single trial, and no study shows garlic prevents heart attacks.
Beetroot juice really does lower blood pressure — the effect is one of the better-documented in food science, driven by dietary nitrate. But most trials are short and small, and no study shows it prevents heart attacks.
A brief swim of light-headedness on standing is usually orthostatic hypotension: a fall in blood pressure as gravity pulls blood to the legs. It is common, rises with age, and often traces to dehydration or medication.
A 21,442-person trial of cocoa flavanol extract missed its main heart target. The blood-pressure effect is real but small — and nearly half of dark chocolate products exceeded a strict lead limit.
For a healthy adult an occasional can is unlikely to harm. But in a randomised trial, 32 ounces raised blood pressure and prolonged the heart's QT interval more than placebo — and paediatricians say no to children.
Eating more potassium lowers blood pressure in people who already have hypertension, and a large trial of potassium-enriched salt cut strokes and deaths — but the benefit is not for everyone.
Pooled trials show a genuine but small fall in blood pressure, around 2 mmHg. The bigger pitches — sleep, cramps, energy, anxiety — run ahead of the evidence.
A landmark trial pushed blood pressure hard and cut mild cognitive impairment — but its headline dementia result fell short of significance after the study stopped early. The pooled trial evidence is real, and modest.
Pooled randomised trials show caffeine pushes blood pressure up sharply in the hour after a dose. But when the caffeine arrives as coffee, and over weeks rather than minutes, the effect shrinks toward nothing.
A meta-analysis of four small trials found zilebesiran lowered office systolic pressure by 7.16 mmHg versus placebo, with wide confidence intervals, a hint the effect wanes by six months, and more hyperkalaemia.
The Hypotension Prediction Index warns anaesthetists before blood pressure falls. Three 2026 trials find a plain mean-pressure alarm does the same job, and the algorithm's benefit tracks how hard clinicians treat.
Medicare paid over $500 million for remote monitoring in 2024, but a watchdog found 43% of patients didn't get the full service — and rigorous evidence that it improves outcomes remains limited.
Toilet seats and mirrors that read your heart and blood pressure are real engineering. The published validation is mostly small, single-lab or company-run — and outcome evidence is absent.
Out-of-office readings predict heart attacks and death better than a clinic measurement, and guidelines now require them to confirm hypertension — but only a validated upper-arm cuff counts.
Two controlled-feeding trials found a diet rich in fruit, vegetables and low-fat dairy lowered blood pressure, most in people who already had hypertension, and more still when sodium was cut.
Applying the 2025 AHA/ACC guideline to a Nigerian survey sharply raised the share classified hypertensive versus older criteria, widening the gap between diagnosis and treatment capacity.
Kidney disease is usually silent until it is advanced, and most of it traces to diabetes and high blood pressure. Controlling those two, and getting tested, is the highest-yield protection — not kidney superfoods.
European hypertension specialists found only two wrist-cuff blood pressure watches with validation studies done to established protocols. A sleep group ran a Galaxy Watch against two nights of polysomnography.
A 2023 network meta-analysis of 270 trials ranked isometric exercise first for lowering resting blood pressure. Two 2026 analyses, using ambulatory monitoring and a larger trial set, rank it among the weakest.
In people who already have kidney disease, cutting salt reduced albuminuria by about 36% and lowered blood pressure. High salt also blunts standard kidney-protecting drugs — though long-term outcome trials are missing.
Global mean intake was 4,278 mg a day in 2021 against a recommended limit under 2,000. A week of low-sodium eating moved blood pressure in most people; a five-year trial of salt substitute cut strokes.
In the phase 3 Launch-HTN trial, adults already on two to five drugs fell 9.1 mm Hg further on lorundrostat than placebo — the second aldosterone-synthase inhibitor to post positive data after baxdrostat.
A dose-response analysis of 23 cohort studies found hypertension risk climbing steadily with intake. Stopping for a month, a separate study found, dropped systolic pressure by nearly 7%.
American guidelines call 130/80 stage 1 hypertension. European ones call the same reading elevated blood pressure and not yet disease. The measurement did not change. The label did.
After four weeks, the comorbid-insomnia group's blood pressure fell 20 points more than the apnea-only group. The finding flips the usual framing of COMISA as simply a worse-outcomes phenotype.
In moderate-to-heavy drinkers who stopped for a month, insulin resistance fell by a quarter and two cancer-related growth factors dropped sharply — changes a matched control group did not show.
In 377 patients, hypoxic burden — a metric combining how often, how deep, and how long oxygen drops — tracked with abnormal nighttime blood pressure patterns where conventional measures didn't.
In 230 adults followed a year, lower heart-rate variability and less moderate-to-vigorous activity at baseline were independently linked to developing hypertension. It is a risk signal, in one unreplicated cohort.
A February scientific statement declines to recommend the category for clinical decisions. Six weeks earlier, a journal retracted a validation study of a popular consumer model.
FDA-cleared in September 2025, the feature notifies fewer than half of people with hypertension in Apple's own validation. Hypertension specialists warn the bigger risk is false reassurance.
The FDA's revised general wellness policy lets non-invasive devices infer blood pressure, glucose and other physiologic parameters. The regulated line is no longer the measurement — it is the sentence next to it.
A meta-analysis of pedometer, tracker and smartwatch interventions lasting 12 to 48 weeks found no significant change in systolic or diastolic pressure — nor in weight, glucose or HbA1c.
Applying prevalence figures to UN population data yields 852 million adults with insomnia. Only 31 of 237 countries had a usable national estimate of their own.